Our primary focus is immuno-oncology. In addition, we also develop the next generation therapies for eye diseases.
Technology Platforms
Phanes' two technology platforms are designed to build native IgG-like bispecific antibodies that enhance drug-like properties. PACbodyTM: Build native IgG-like bispecific antibodies. ATACCbodyTM: Build bispecific antibodies with modulated activities.
